Related Experiment Video
Updated: Feb 10, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management
Gabriela Leuschner1, Fredrik Reiter2, Florian Stocker2
1Department of Internal Medicine V, Comprehensive Pneumology Centre (CPC-M), Member of the German Centre for Lung Research (DZL), Ludwig-Maximilian University Munich, Marchioninistrasse 15, 81377, Munich, Germany. gabriela.leuschner@med.uni-muenchen.de.
Insights
Younger patients with idiopathic pulmonary fibrosis (IPF) show similar disease characteristics and clinical course. Early diagnosis and antifibrotic therapy may improve outcomes for these patients.
Area of Science:
- Pulmonology
- Internal Medicine
- Geriatrics
Background:
- Idiopathic pulmonary fibrosis (IPF) is typically a disease of older adults.
- IPF in patients 50 years or younger is uncommon and poorly characterized.
Purpose of the Study:
- To compare diagnostic certainty, clinical features, comorbidities, and survival in young (<50 years) versus older (≥50 years) IPF patients.
Main Methods:
- Retrospective review of 129 IPF patients (30 young, 99 older) diagnosed between February 2011 and February 2015.
- Analysis of radiographic, histological, lung function, comorbidity, progression, and survival data.
Main Results:
- Younger IPF patients were less likely to have high-resolution CT confirmed diagnosis and antifibrotic therapy.
- Despite similar features, younger patients had significantly better median survival post-diagnosis.
- Older IPF patients had a higher mortality rate due to respiratory failure.
Conclusions:
- IPF patients under 50 share clinical features and course with older counterparts.
- A multidisciplinary approach and earlier antifibrotic therapy may benefit younger IPF patients.
Introduction:
Idiopathic pulmonary fibrosis (IPF) is considered a disease of older patients, being rare in patients ≤ 50 years. Still, IPF can occur in younger patients, but this particular patient group is not well characterised so far. The aim of this study was to compare the diagnostic certainty, clinical features, comorbidities and survival in young versus older IPF patients.
Methods:
We reviewed our medical records from February 2011 until February 2015, to identify IPF patients, who were then classified as young (≤ 50 years) or older IPF (> 50 years). Radiographic and histological findings, lung function parameters, comorbidities, disease progression and survival were analysed and compared between the two groups.
Results:
Of 440 patients with interstitial lung disease, 129 patients with IPF were identified, including 30 (23.3%) ≤50 years and 99 (76.7%) > 50 years. There were no differences between age groups in baseline demographics; younger patients were less likely to have a confirmed diagnosis by high-resolution computed tomography (p = 0.014), more likely to require a biopsy (p = 0.08) and less likely to have received antifibrotic therapy (p = 0.006). Despite an overall limited prognosis, younger patients had a significantly better median survival after diagnosis (p = 0.0375), with a significantly higher proportion of older patients dying due to respiratory failure (p = 0.0383).
Conclusion:
IPF patients under the age of 50 years have similar features and clinical course compared to older IPF patients. These patients should be diagnosed by adopting a multidisciplinary team approach, potentially benefitting from earlier intervention with effective antifibrotic therapy.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Pulmonary Embolism III: Nursing Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Nursing Process for Patient and Caregiver Teaching I: Assessment and Diagnosis
It is critical to determine the patient's learning needs during the assessment. Determination of learning needs compounds data...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

